PDCD1 and non-small cell lung carcinoma: The anti-CTLA-4 immunotherapeutic agent ipilimumab has demonstrated promising results in improving SCLC and NSCLC patient outcomes, while nivolumab (anti-PD-1 therapy) has been approved by the Food and Drug Administration (FDA) for the treatment of advanced squamous and non-squamous NSCLC [76–80].